





Valuation process for a given RG or CTA: most frequent current situations







1: Access to GR and/or aTK

=> **EXPORT** (Traders)

2 & 3 & 4: aah national level, steps not visible => no added values within the country of origin







=> Stages B & C take place preferably in the country of origin A B S reinforces the competitiveness of national economic operators



Exemple: some numbers about the pharmaceutical industry*

* More than a third of modern medicines derive directly or indirectly from biological resources (plants, animals, microorganisms)

* 60 to 80% of antibiotics and anticancer drugs come from Biodiversity

* +/- 4 billion people mainly depend on natural medicines

=> "Access to medicines threatened by the collapse of biodiversity"

Biodiversity: a public health tool



* Evolution of "post-COVID" consumer demands: accelerated paradigm shift management

- => "The new Consumers Actors": strengthened global movement for more ethics, traceability and quality for consumer products
- => (re-) localization of the production of essential products / increase in autonomy at the national level
- => increased demand for "natural" products (resulting from the enhancement of biodiversity)

Strategic Considerations:

- => "Consumer actors" make the market and influence the practices of the private sector
- => New economic models (including the benefits to be shared and considerations of sustainable use) must be built during the development of new sectors



- Health security responses to national needs / Sustainable Development Goals
- Economic diversification / development of a bio-economy within the country, based on the valorization of genetic resources and associated Traditional Knowledge.
- Actors of change / competitiveness: companies "with mission" / sectorial contribution to the challenges of biodiversity loss, fight against climate change "marketing power"



Thank you for your attention

Questions